Dr. Yochai Wolf

Principal Investigator, R & D lab

Ella Lemelbaum Institute for Immuno-oncology

Sheba Medical Center, Israel

Assistant Professor, Department of Pathology

Faculty of Medicine, Tel Aviv University


Dr. Yochai Wolf received his PhD in Immunology at the Weizmann Institute of Science, studying the role of macrophages in health and disease (2010-2016) .


He then decided to focus his career on cancer immunology and started his first postdoctoral training, also at the Weizmann Institute, studying the interactions between tumor heterogeneity and cancer immunology (2016-2018). He later moved to Boston, MA, USA, for his second postdoctoral training at Harvard Medical School and Brigham and Women’s hospital, studying the role of the novel checkpoint molecule TIM-3 in cancer and autoimmunity (2018-2021).


Dr. Wolf have joined Sheba Medical Center and is now the Head of the research and development at the Ella Lemelbaum Institute for immuno-oncology and melanoma, a world-class center for cancer therapeutics, clinical trials, and research.


He is also an assistant professor at the Department of Pathology, School of Medicine, Tel Aviv University.  His field of research consists of T cell engineering for adoptive cell therapy for melanoma  using mRNA and CRISPR; Development of novel TCR therapy for rare melanomas; establishment of new CAR-T cell modalities; and microbial involvement in cancer immunotherapy.



Contact info:







Tel Aviv University makes every effort to respect copyright. If you own copyright to the content contained
here and / or the use of such content is in your opinion infringing, Contact us as soon as possible >>